Barriers to accessing medications for opioid use disorder among rural individuals

Access barriers vary by MOUD type for rural individuals with OUD. Compared to sublingual buprenorphine, methadone access was hindered more by transportation difficulties, while injectable long-acting buprenorphine was hindered more by affordability and finding a doctor or program. These barriers highlight the need to de-regulate and expand locations for methadone access and prescribing, and to improve affordability and prescriber uptake of newer MOUDs, such as injectable buprenorphine.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Policy
Published
2025-04-19
DOI
https://doi.org/10.1016/j.drugpo.2025.104805
Citations
9
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
16.91

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Barriers to accessing medications for opioid use disorder among rural individuals

Thomas J. Stopka, David W. Seal, Joseph A. Delaney, Gordon S. Smith et al.
9 citations
International Journal of Drug Policy
Opioid Use Disorder Treatment
16.91
article

Barriers to accessing medications for opioid use disorder among rural individuals

Thomas J. Stopka, David W. Seal, Joseph A. Delaney, Gordon S. Smith, Judith Feinberg, Wiley D. Jenkins, P. Todd Korthuis, Peter D. Friedmann, William A. Zule, L. Sarah Mixson, Ryan P. Westergaard, Vivian F. Go, Heidi M. Crane, William C. Miller, Judith I. Tsui, Anna M. Morenz, Robin M. Nance, Laura C. Fanucchi, Mai T. Pho
article en
9 citations

Abstract

Access barriers vary by MOUD type for rural individuals with OUD. Compared to sublingual buprenorphine, methadone access was hindered more by transportation difficulties, while injectable long-acting buprenorphine was hindered more by affordability and finding a doctor or program. These barriers highlight the need to de-regulate and expand locations for methadone access and prescribing, and to improve affordability and prescriber uptake of newer MOUDs, such as injectable buprenorphine.

International Journal of Drug PolicyVol. 140
University of North Carolina at Chapel Hill (US), Tulane University (US), West Virginia University (US), Tufts University (US), University of Wisconsin–Madison (US), University of Arizona (US), University of Kentucky (US), Oregon Health & Science University (US), RTI International (US), University of Washington (US), University Press of Kentucky (US), University of Chicago (US), Baystate Health (US), Clemson University (US)
National Institutes of Health, Centers for Disease Control and Prevention, Substance Abuse and Mental Health Services Administration, Australian Research Council, National Institute on Drug Abuse, National Institute of Diabetes and Digestive and Kidney Diseases
Openalex Percentile: Top 1%
Opioid Use Disorder Treatment
16.91
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.